Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists.
M W Taal, B M Brenner
https://pubmed.ncbi.nlm.nih.gov/10792600/Actively Recruiting
Led by Region Skane · Updated on 2025-06-22
30
Participants Needed
4
Research Sites
N/A
Total Duration
Researchers are evaluating aliskiren, a direct renin inhibitor, as a new treatment option for patients with C3 glomerulopathy, a kidney disease caused by complement system activation. This study compares aliskiren to the current standard treatment, enalapril, an angiotensin converting enzyme inhibitor ACEi. The goal is to see if aliskiren can better reduce complement activation in the kidneys, which may stabilize or improve kidney function. This is a phase 2, randomized, open-label, controlled cross-over trial involving patients with this complement-mediated renal disease. Participants will be randomly assigned to start treatment with either aliskiren tablets 150-300 mg daily or enalapril tablets 2.5-20 mg daily for the first 6 months. After this period, they will switch to the other treatment for the next 2.5 years, completing a total of 3 years of treatment. Dosing schedules may vary between once or twice daily depending on the medication and patient weight. The study also includes an extension phase with repeat kidney biopsies to assess complement deposition and kidney tissue changes. During the study, patients will have routine follow-up visits every 3 months with their own nephrologist. These visits will include blood and urine tests to monitor kidney function, protein levels, renin and complement system activity using various assays. Kidney biopsies will be performed at the start and again after 1 to 3 years to evaluate treatment effects on kidney structure. The study measures primary outcomes such as serum C3 levels and complement deposits in the kidneys, along with secondary outcomes like proteinuria, blood pressure, and other complement activation markers.
CONDITIONS
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
D
Diana Karpman, MD PhD
Z
Zivile Bekassy, MD PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Region Skane
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 3 years total
Participants receive oral tablet treatment starting with either aliskiren or enalapril for 6 months, then switch to the other drug for the following 2.5 years.
Routine visits every 3 months for monitoring renal function, blood pressure, and blood samples.
Duration - Up to 3 years
Participants are followed by their own nephrologist with routine clinical care and monitoring for up to 3 years, including repeat kidney biopsy when medically indicated to assess treatment effects.
Routine clinical visits every 3 months; repeat kidney biopsy once between 1 to 3 years after treatment start.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
M W Taal, B M Brenner
https://pubmed.ncbi.nlm.nih.gov/10792600/Zivile D Békássy, Ann-Charlotte Kristoffersson, Johan Rebetz...
https://pubmed.ncbi.nlm.nih.gov/29884545/Richard J H Smith, Gerald B Appel, Anna M Blom...
https://pubmed.ncbi.nlm.nih.gov/30692664/Region Skane
Lead Sponsor